Risk of Sarcopenia Identified by Sarc-Calf, Nutritional Status and Hand Grip Strength in Patients with Hematological Cancer
View abstract on PubMed
Summary
This summary is machine-generated.The SARC-CalF tool identified a significant risk of sarcopenia in 39.2% of hematological cancer patients. Reduced Hand Grip Strength (HGS) was strongly associated with this sarcopenia risk, highlighting its importance in this vulnerable population.
Area Of Science
- Oncology
- Geriatrics
- Nutritional Science
Background
- Hematological cancer patients often experience sarcopenia, impacting their nutritional and functional status.
- The SARC-CalF screening tool has demonstrated efficacy in assessing sarcopenia risk within this patient group.
- Understanding sarcopenia risk is crucial for managing the overall health of cancer patients.
Purpose Of The Study
- To identify the prevalence of sarcopenia risk using the SARC-CalF tool in hematological cancer patients.
- To investigate the association between sarcopenia risk, nutritional status (PG-SGA), and muscle strength (HGSD, APMTD).
- To validate the SARC-CalF tool's effectiveness in this specific oncological population.
Main Methods
- A cohort of adult, outpatient hematological cancer patients was assessed.
- Measurements included Hand Grip Strength of the Dominant Hand (HGSD) and Adductor Pollicis Muscle Thickness of the Dominant Hand (APMTD).
- Nutritional status was evaluated using the Patient-Generated Subjective Global Assessment (PG-SGA), and sarcopenia risk was assessed with SARC-CalF.
Main Results
- 39.2% of patients screened positive for sarcopenia risk via SARC-CalF.
- Significant associations were observed between SARC-CalF results and diagnosis duration, PG-SGA scores, APMTD, and HGSD.
- Reduced HGSD was independently associated with an increased risk of sarcopenia after adjusting for age and sex.
Conclusions
- The SARC-CalF tool effectively identifies a substantial proportion of hematological cancer patients at risk for sarcopenia.
- Reduced Hand Grip Strength is a key indicator linked to sarcopenia risk in this population.
- These findings underscore the need for early screening and intervention for sarcopenia in hematological cancer patients.

